Twist Bioscience Corp has disclosed an update regarding its beneficial ownership in a recent filing. FMR LLC, a major investment firm, now holds approximately 14.4% of Twist's common stock. This change is significant as it reflects FMR LLC's continued confidence in the company and its growth potential within the biological products sector.

Twist Bioscience Corp, based in South San Francisco, operates in the biological products industry, specifically classified under SIC 2836, which includes companies engaged in the production of biological products (excluding diagnostic substances). The company trades under the ticker TWST on the Nasdaq exchange and is categorized as a large accelerated filer.

The recent filing, dated November 5, 2026, is a Schedule 13G/A, indicating an amendment to a previous filing. It reveals that FMR LLC beneficially owns 9,535,192.79 shares of Twist Bioscience, with sole voting and dispositive power over these shares. The filing states, "One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of TWIST BIOSCIENCE CORP." This suggests that FMR LLC is not the only significant stakeholder in the company.

FMR LLC's substantial ownership may influence various stakeholders, including other investors and analysts, as it reflects a strong endorsement of Twist Bioscience's business model and market position. The filing also highlights Abigail P. Johnson, the CEO of FMR LLC, as a key figure in this investment, suggesting a personal commitment to the company's future.

What's next for Twist Bioscience remains unclear, as the filing does not specify any immediate actions or upcoming events related to this ownership change. Investors and market watchers will likely keep a close eye on future filings and developments from the company.